2,4-디클로로벤질 알코올

This chemical does not meet GHS hazard criteria for 0.2% (1 of 400) of reports.

Danger

H318 (31.2%): Causes serious eye damage [Danger Serious eye damage/eye irritation]；H332 (28.7%): Harmful if inhaled [Warning Acute toxicity, inhalation]；H412 (96.8%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard]

P261, P264+P265, P271, P273, P280, P304+P340, P305+P354+P338, P317, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 400 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Reported as not meeting GHS hazard criteria per 1 of 400 reports by companies.；There are 9 notifications provided by 399 of 400 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Chemical: Benzenemethanol, 2,4-dichloro-

Status: Active Update: 13-04-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/23988

2,4-Dichlorobenzyl alcohol: Does not have an individual approval but may be used under an appropriate group standard

Chemical: Benzenemethanol, 2,4-dichloro-

Status: Active Update: 13-04-2021 https://echa.europa.eu/registration-dossier/-/registered-dossier/23988

2,4-Dichlorobenzyl alcohol: Does not have an individual approval but may be used under an appropriate group standard

R - Respiratory system；R02 - Throat preparations；R02A - Throat preparations；R02AA - Antiseptics；R02AA03 - Dichlorobenzyl alcohol

QR - Respiratory system；QR02 - Throat preparations；QR02A - Throat preparations；QR02AA - Antiseptics；QR02AA03 - Dichlorobenzyl alcohol

In vitro studies with the combination of dichlorobenzyl alcohol and amylmetacresol have shown a virucidal against a number of viruses associated with the common cold which is observed by a reduction in the viral load. In clinical trials, administration of dichlorobenzyl alcohol lozenges has been shown to generate a reduced throat soreness and to provide pain relief and relief from difficulty in swallowing 5 minutes after administration. This effect can last for even 2 hours. The relief effect was shown to reach a steady-state after 45 minutes.

The use of dichlorobenzyl alcohol has been related to its antibacterial, antiviral and local anesthetic properties. The local anesthetic action of dichlorobenzyl alcohol is thought to be due to a reduced sodium channel blockade. The antiseptic mechanism of action of dichlorobenzyl alcohol is not fully understood but it is thought to be related to a denaturation of external proteins and rearrangement of the tertiary structure proteins.

Dichlorobenzyl alcohol is released almost immediately from its formulation and reaches peak concentration after 3-4 minutes. The concentration in saliva after 120 minutes represents about 50% of the administered dose.

In preclinical trials, dermal administration of dichlorobenzyl alcohol results in renal elimination of 90% of the administered dose. After metabolism, dichlorobenzyl alcohol is excreted in the urine.

This pharmacokinetic property has not been fully studied.

This pharmacokinetic property has not been fully studied.